[Sulbactam/ampicillin in the treatment and prevention of urologic diseases].
Efficacy and safety of unasyn, a combination of sulbactam and ampicillin, was studied in the treatment of 66 patients with infections of the urogenital organs. The drug was administered intramuscularly, intravenously and orally. The treatment course averaged 7-14 days. The dose of the drug for the intravenous and intramuscular administration was 1.5-3 g 4 times a day and that for the oral administration was 0.75 g 2 times a day. The strains of gram-positive cocci, Escherichia coli and Proteus spp. proved to be highly sensitive to the drug: 80-83, 43 and 53 per cent of the sensitive strains respectively. 25-75 per cent of the strains showed beta-lactamase activity that was most frequently detected in Proteus spp. and Staphylococcus spp. The maximum concentrations of ampicillin and sulbactam determined by liquid chromatography were respectively 18 +/- 5.7 and 11 +/- 2.42 micrograms/ml in the blood and 700 and 350 micrograms/ml in the urine. A satisfactory bacteriological effect of the treatment was observed in 93 per cent of the cases. A complete elimination of the initial pathogens was stated in 57-73 per cent of the cases. No side effects were recorded.
Perepanova
T S
TS
Kotliarova
G A
GA
Kondrat'eva
E M
EM
Siniukhin
V N
VN
Safin
R N
RN
D000328:Adult; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases / Q000188:drug therapy* / Q000517:prevention & control; D008826:Microbial Sensitivity Tests; D013407:Sulbactam / Q000009:adverse effects / Q000627:therapeutic use
D000667:Ampicillin; D013407:Sulbactam
Sul'baktam/ampitsillin v lechenii i profilaktike urologicheskikh zabolevaniĭ.